humira_abbott__4

International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition

pharmafile | November 4, 2019 | News story | Sales and Marketing AbbVie, Humira, pharma 

With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – the best-selling drug in the world – had taken a considerable hit in the face of biosimilar competition, falling 33.5% on a reported basis.

Total global revenues for the drug stood at $4.936 billion, a much stronger showing compared to the $1.049 billion generated internationally, and only fell by 3.7% overall. This was helped largely by US revenues, where sales for the drug actually increased by 9.6% as a result of a complete lack of biosimilar competition in the region until 2023.

The figures show just how much of a threat biosimilar therapy alternatives pose to the market dominance of products like Humira, and also why AbbVie has been so keen to protect its market exclusivity in the US.

They also illustrate the success of these biosimilar alternatives in the EU market, with recent IQVIA data indicating that adalimumab has a 57% uptake across the region’s five key national markets while discounts for the drug have reached 70-80%.

AbbVie will be counting on the successes of its rheumatoid arthritis drug Rinvoq and plaque psoriasis therapy risankizumab to make up for these diminishing returns which will surely shrink further in coming years; Humira’s sales accounting for 61% of the company’s total revenues in 2018, and this had fallen to 27.9% by the first quarter of 2019.  

Matt Fellows

Related Content

Medincell and AbbVie enter agreement for development of next-generation injectables

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …

AbbVie to acquire Landos Biopharma for approximately $137.5m

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …

AbbVie and Tentarix collaborate on oncology and immunology treatments

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on …

Latest content